The Cytocom approach is to deploy its patented therapies focused on the activation and rebalancing of the body’s immune system. The company argues that stimulating the immune system remains one of the most promising approaches in the treatment of cancers, HIV, autoimmune diseases, inflammatory conditions and other chronic infectious diseases.

In July 2020, the Florida-based company announced the acquisition of ImQuest Life Sciences, a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries, in an all-stock transaction.